Pacira BioSciences, Inc. [PCRX] - Viatris / Pacira BioSciences tender offer
Viatris and Purchaser have initiated a tender offer for all outstanding shares of Pacira BioSciences, with the offer set to expire on November 16, 2026.
Why this matters
Pacira BioSciences, Inc., a Delaware-incorporated company in the pharmaceutical preparations industry, primarily focuses on developing and commercializing non-opioid pain management and regenerative health solutions, with its flagship product being EXPAREL, a bupivacaine liposome injectable suspension. Viatris and a designated Purchaser have initiated a tender offer to acquire all outstanding shares of Pacira BioSciences, with the offer set to expire on November 16, 2026. This move follows a strategic review by Pacira, which concluded that the merger would likely create more value for its stockholders compared to remaining a standalone entity, given various risks including patent litigation and market challenges.